Qualit-E-SpeakPharma-Insert
X

Find drug development pipeline and deal Updates information

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Apabetalone,Atorvastatin

            Therapeutic Area: Endocrinology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 30, 2020

            Details:

            Apabetalone recently completed the first ever Phase 3 clinical trial of a BET inhibitor for a cardiovascular disease indication.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dasiglucagon

            Therapeutic Area: Endocrinology

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 30, 2020

            Details:

            Single mini-doses of dasiglucagon effectively reduced time spent in hypoglycemia after meals in individuals who have undergone bariatric surgery.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hydrocortisone

            Therapeutic Area: Endocrinology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eton Pharmaceuticals

            Deal Size: $7.5 million Upfront Cash: $3.5 million

            Deal Type: Licensing Agreement March 27, 2020

            Details:

            The acquisition advanced Eton’s leadership in pediatric rare diseases products providing a $100 million market opportunity.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Teplizumab

            Therapeutic Area: Endocrinology

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 16, 2020

            Details:

            PROTECT Study Randomization to be Paused Temporarily in Response to the Ongoing Public Health Crisis

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Exenatide

            Therapeutic Area: Endocrinology

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: National Securities Corporation

            Deal Size: $21.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering February 27, 2020

            Details:

            The Company intends to use the net proceeds of the offering for its anticipated Phase 3 clinical trial in ORMD-0801 and for other clinical trials and R&D activities.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Testosterone Undecanoate

            Therapeutic Area: Endocrinology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 24, 2020

            Details:

            The FDA requested that the information generated by the reanalysis be submitted as part of an NDA resubmission with a six-month Prescription Drug User Fee Act clock.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Apabetalone

            Therapeutic Area: Endocrinology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 03, 2020

            Details:

            FDA has granted Breakthrough Therapy Designation for apabetalone in combination with high-intensity statins, for the secondary prevention of MACE in patients with type 2 DM and recent ACS.